OBJECTIVE: To examine the association between maternal and fetal genetic variants and small-for-gestational-age (SGA). METHODS: A case-control study was conducted in patients with SGA neonates (530 maternal and 436 fetal) and controls (599 maternal and 628 fetal); 190 candidate genes and 775 SNPs were studied. Single-locus, multi-locus and haplotype association analyses were performed on maternal and fetal data with logistic regression, multifactor dimensionality reduction (MDR) analysis, and haplotype-based association with 2 and 3 marker sliding windows, respectively. Ingenuity pathway analysis (IPA) software was used to assess pathways that associate with SGA. RESULTS: The most significant single-locus association in maternal data was with a SNP in tissue inhibitor of metalloproteinase 2 (TIMP2) (rs2277698 OR = 1.71, 95% CI [1.26-2.32], p = 0.0006) while in the fetus it was with a SNP in fibronectin 1 isoform 3 preproprotein (FN1) (rs3796123, OR = 1.46, 95% CI [1.20-1.78], p = 0.0001). Both SNPs were adjusted for potential confounders (maternal body mass index and fetal sex). Haplotype analyses resulted in associations in α 1 type I collagen preproprotein (COL1A1, rs1007086-rs2141279-rs17639446, global p = 0.006) in mothers and FN1 (rs2304573-rs1250204-rs1250215, global p = 0.045) in fetuses. Multi-locus analyses with MDR identified a two SNP model with maternal variants collagen type V α 2 (COL5A2) and plasminogen activator urokinase (PLAU) predicting SGA outcome correctly 59% of the time (p = 0.035). CONCLUSIONS: Genetic variants in extracellular matrix-related genes showed significant single-locus association with SGA. These data are consistent with other studies that have observed elevated circulating fibronectin concentrations in association with increased risk of SGA. The present study supports the hypothesis that DNA variants can partially explain the risk of SGA in a cohort of Hispanic women.
OBJECTIVE: To examine the association between maternal and fetal genetic variants and small-for-gestational-age (SGA). METHODS: A case-control study was conducted in patients with SGA neonates (530 maternal and 436 fetal) and controls (599 maternal and 628 fetal); 190 candidate genes and 775 SNPs were studied. Single-locus, multi-locus and haplotype association analyses were performed on maternal and fetal data with logistic regression, multifactor dimensionality reduction (MDR) analysis, and haplotype-based association with 2 and 3 marker sliding windows, respectively. Ingenuity pathway analysis (IPA) software was used to assess pathways that associate with SGA. RESULTS: The most significant single-locus association in maternal data was with a SNP in tissue inhibitor of metalloproteinase 2 (TIMP2) (rs2277698 OR = 1.71, 95% CI [1.26-2.32], p = 0.0006) while in the fetus it was with a SNP in fibronectin 1 isoform 3 preproprotein (FN1) (rs3796123, OR = 1.46, 95% CI [1.20-1.78], p = 0.0001). Both SNPs were adjusted for potential confounders (maternal body mass index and fetal sex). Haplotype analyses resulted in associations in α 1 type I collagen preproprotein (COL1A1, rs1007086-rs2141279-rs17639446, global p = 0.006) in mothers and FN1 (rs2304573-rs1250204-rs1250215, global p = 0.045) in fetuses. Multi-locus analyses with MDR identified a two SNP model with maternal variants collagen type V α 2 (COL5A2) and plasminogen activator urokinase (PLAU) predicting SGA outcome correctly 59% of the time (p = 0.035). CONCLUSIONS: Genetic variants in extracellular matrix-related genes showed significant single-locus association with SGA. These data are consistent with other studies that have observed elevated circulating fibronectin concentrations in association with increased risk of SGA. The present study supports the hypothesis that DNA variants can partially explain the risk of SGA in a cohort of Hispanic women.
Authors: Anthony O Odibo; Deborah Nelson; David M Stamilio; Harish M Sehdev; George A Macones Journal: Am J Perinatol Date: 2006-06-23 Impact factor: 1.862
Authors: Digna R Velez; Bill C White; Alison A Motsinger; William S Bush; Marylyn D Ritchie; Scott M Williams; Jason H Moore Journal: Genet Epidemiol Date: 2007-05 Impact factor: 2.135
Authors: Lisa M Bodnar; Janet M Catov; Joseph M Zmuda; Margaret E Cooper; Meredith S Parrott; James M Roberts; Mary L Marazita; Hyagriv N Simhan Journal: J Nutr Date: 2010-03-03 Impact factor: 4.798
Authors: Mete Akisu; Zuhal Balim; Hasan Cetin; Buket Kosova; Mehmet Yalaz; Nejat Topcuoglu; Nilgun Kultursay Journal: Early Hum Dev Date: 2004-07 Impact factor: 2.079
Authors: Tinnakorn Chaiworapongsa; Roberto Romero; Francesca Gotsch; Jimmy Espinoza; Jyh Kae Nien; Luis Goncalves; Samuel Edwin; Yeon Mee Kim; Offer Erez; Juan Pedro Kusanovic; Beth L Pineles; Zoltan Papp; Sonia Hassan Journal: J Matern Fetal Neonatal Med Date: 2008-01
Authors: B R Winkelmann; M M Hoffmann; M Nauck; A M Kumar; K Nandabalan; R S Judson; B O Boehm; A R Tall; G Ruaño; W März Journal: Pharmacogenomics J Date: 2003 Impact factor: 3.550
Authors: Quaker E Harmon; Stephanie M Engel; Michael C Wu; Thomas M Moran; Jingchun Luo; Alison M Stuebe; Christy L Avery; Andrew F Olshan Journal: Am J Reprod Immunol Date: 2014-04-04 Impact factor: 3.886
Authors: I Castilla-Cortazar; J R De Ita; G A Aguirre; M García-Magariño; I Martín-Estal; V J Lara-Diaz; M I Elizondo Journal: Endocrinol Diabetes Metab Case Rep Date: 2017-11-09